Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän

Medication in temporomand… - Göteborgs universitet Till startsida
Till innehåll Läs mer om hur kakor används på gu.se

Medication in temporomandibular disorders and bruxism

Författare Birgitta Johansson Cahlin
Datum för examination 2016-06-10
ISBN 978-91-628-9782-6
Publiceringsår 2016
Publicerad vid Institutionen för odontologi
Språk en
Länkar hdl.handle.net/2077/42337
Ämnesord temporomandibular disorders, sleep bruxism, glucosamine sulfate, pramipexole, dopamine agonist, botulinum toxin, cerebral palsy
Ämneskategorier Klinisk medicin


The aim of this thesis was to explore aspects of pharmaceutical intervention in temporomandibular disorders (TMDs) and bruxism. Sleep bruxism is a movement disorder that signals disturbed sleep and constitutes a significant health problem due to TMDs, headache and tooth wear. In Study I, medication was reviewed in patients referred for specialist treatment for TMDs. Female patients with myofascial pain used significantly more psychoactive medication, including antidepressants, tranquilizers, sedatives and hypnotics, compared with matched controls. These findings support other research demonstrating an overrepresentation of the diagnoses depression, anxiety, stress and sleep problems among TMD patients. Study II compared the effect of oral glucosamine sulfate on osteoarthritis in the temporomandibular joints with that of placebo. Glucosamine sulfate appeared to improve signs and symptoms over time, but it was not significantly superior to placebo. In Study III, the dopamine agonist, pramipexole, was investigated in severe sleep bruxism confirmed by polysomnographic/electromyographic monitoring. The severity of sleep bruxism was not reduced compared with control conditions, indicating that the involvement of the dopamine system in bruxism is less likely. In Study IV, the effects of botulinum toxin injections in the masticatory muscles, compared with placebo injections, were evaluated in subjects with cerebral palsy and bruxism. No significant differences between active and control injections in terms of subjective or objective oral functions could be observed at group level. In conclusion, the results were negative with respect to the evaluated pharmacologic remedies for TMDs and bruxism. There is a relative lack of controlled studies in this area. Considering the pronounced negative impact on quality of life that has been reported for these conditions, it should be an important task continuously to evaluate putative pharmacologic therapies in TMDs and bruxism.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?